The Regeneus Board has a broad range of experience in the biotechnology industry, early stage technology companies combined with Australian public company, capital markets, financial and commercial expertise.
John Martin has served on the Board of the Company since early 2009 and has worked closely with the founders to develop and grow the business since that time. He was appointed Chairman in 2010. John has over 20 years of corporate and commercial experience including roles as CEO and director of ASX listed and private companies and executive partner of Allens. He has advised and worked with emerging technology and high growth companies for over 12 years including being a co-founder and director of biotech spin outs from Macquarie University, BTF and Proteome Systems. He is currently a principal of The Channel Group, chairman of Ai-Media and director of Eagle Eye Solutions (Asia Pacific).
Professor Graham Vesey is a co-founder and founding CEO of Regeneus and has served on the Board since incorporation. Graham is a successful biotechnology entrepreneur, technology innovator and inventor on various patents in the biotechnology area and a highly regarded scientist. He has been the primary driver of the Company's R&D programs, product innovation and development and IP portfolio. Prior to co-founding Regeneus, Graham was a co-founder and executive director of BTF, a highly successful Sydney-based biotechnology company and was responsible for developing BTF's product and patent portfolios. In 2007, BTF was acquired by bioMerieux, a French multinational diagnostic company. Graham is an Adjunct Professor at Macquarie University and a Senior Research Fellow at the University of NSW.
Associate Professor Ben Herbert is a co-founder and founding director of the Company and has served on the Board since incorporation. Dr Herbert is a Vice-Chancellor Innovation Fellow and Director of Regenerative Science at Macquarie University where he leads a large stem cell research group that collaborates on R&D projects with the Company. He is a regular presenter at conferences and in the media on regenerative medicine and stem cell technologies. Ben was the former Director of the Proteomics Technology Centre of Expertise at the University of Technology, Sydney, co-founder of Proteome Systems and a key member of the team that set up Australia's first proteomics facility, Australian Proteome Analysis Facility at Macquarie University in 1995.
Dr Roger Aston is one of the most experienced and commercially astute people in drug commercialisation in Australia. Roger brings more than 20 years experience in the pharmaceutical and healthcare industries in senior roles in the United Kingdom, Asia-Pacific and Australia. Roger has held executive, non-executive director or chairman positions on a number of boards including Peptech Limited (Arana), Cambridge Antibody Technology Limited, Clinuvel Limited, Halcygen Limited, Cambridge Drug Discovery, and pSivida Limited. He started his career at major pharmaceutical company Wellcome (now Glaxo Smith Kline) and has also worked for QinetiQ Limited. Roger also served on the federal government's IRD board sub-committee for biologicals. Roger was formerly CEO of Mayne Pharma Group Limited and currently is a director and CEO of Pitney Pharmaceuticals Pty Ltd, Chairman of BioLife Limited, Chairman of Immuron Limited, Director of IDT Limited, Chairman of Cynata Limited and Chairman elect of NeuroDiscovery Limited.
Barry Sechos is a non-executive director who has served as an alternate director since 2011 and became a full director in June 2012. He has over 25 years experience as a director, business executive and corporate lawyer. Barry is a Director of the Sherman Group (a strategic investor in the Company), a privately owned investment company. Barry is also a director of See-Saw Films, a film production and finance group and winner of the 2011 Academy Award for Best Picture, Transmission Films, a film distribution company, Customers Ltd, an ATM deployment company and Sherman Contemporary Art Foundation, a charitable cultural organisation. He previously held various positions with the Aberdeen Asset Management/EquitiLink Funds Management Group including Director of Aberdeen Asset Management, General Counsel and Compliance Officer to Equitilink Group and EquitiLink International Management. Barry commenced his professional career as a commercial lawyer at Allen Allen & Hemsley in Sydney, Singapore and London.